Tumor selective and biodegradable...

Details Tumor selective and biodegradable... Tumor selective and biodegradable...

2005-10-04

2005-10-04

Nazario-Gonzalez, Porfirio (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heavy metal containing

C556S013000, C525S538000, C514S492000, C424S078310, C424S078050

Reexamination Certificate

active

06951953

ABSTRACT:
Disclosed are a new class of a polyphosphazene-platinum(II) conjugate antitumor agent having high tumor tissue selectivity due to its enhanced permeability and retention effect to tumor tissues, and a preparation method thereof:wherein x represents the number of the ethylene oxide repeating unit and is 7, 12 or 16; y is 0, 1 or 2; z represents molar content of polyethylene glycol in the range of 0.5-1.5; n represents degree of polymerization of polyphosphazene in the range of 30-100; and A-A represents a diamine.

REFERENCES:
patent: 4151185 (1979-04-01), Allcock et al.
patent: 5665343 (1997-09-01), Sohn et al.
patent: 6392008 (2002-05-01), Allcock et al.
Song et al., Polymer International, vol. 48, No. 8, pp. 627-629 (1999).
Song et al., Journal of Controlled Release, vol. 55, No. 2-3, pp. 161-170 (1998).
Sohn et al., International Journal of Pharmaceutics, vol. 153, No. 1, pp. 79-91 (1997).
D. Lebwohl et al., “Clinical Development of Platinum Complexes in Cancer Therapy: An Historical Perspective and an Update,” European Journal of Cancer, vol. 34, No. 10, pp. 1522-1534, 1998.
E. Wong et al., “Current Status of Platinum-Based Antitumor Drugs,” Chem. Rev., vol. 99, pp. 2451-2466, 1999.
L. Seymour et al., “Influence of Molecular Weight on Passive Tumor Accumulation of a Soluble Macromalecular Drug Carrier,” European Journal of Cancer, vol. 31A, No. 5, pp. 766-770, 1995.
R. Duncan., “Polymer Conjugates for Tumor Targeting and Intracytoplasmic Delivery. The EPR Effect as a Common Gateway,” PSTT, vol. 2, No. 11, pp. 441-449, 1999.
H. Maeda et al., “Vascular Permeability Enhancement in Solid Tumor: Various Factors, Mechanissms Involved and its Implications,” International Immunopharmacoclogy, vol. 3, pp. 319-328, 2003.
E. Marecos, “Antibody-Medicated Versus Nontargeted Delivery in a Human Small Cell Lung Carcinoma Model,” Bioconjugate Chem., vol. 9, pp. 184-191, 1998.
A. Lundberg et al., “Control of the Cell and Apoptosis,” European Journal of Cancer, vol. 35, No. 4, p. 531-539, 1999.
K. Tsuchiya et al., “Tumor-Targeted Chemotherapy with SMANCS in Lipiodol for Renal Cell Carcinoma: Llonger Survival with Larger Size Tumors,” Adult Urology, vol. 55, No. 4, pp. 495-500, 2000.
P. Vassey et al., “Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)Methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents- Drug-Polymer Conjugates,” Clinical Cancer Research, vol. 5, pp. 83-94, 1999.
H. Allcock et al., “Synthesis of High Polymeric Alkoxy-and Aryloxyphosphonitriles,” Journal of the American Cancer Society, vol. 87, No. 18, pp. 4216-4217, 1965.
Y. Sohn et al., “Synthesis and Properties of Low Molecular Weight Polyphosphazenes,” Macromolecules, vol. 28, No. 22, pp. 7566-7568, 1995.
S. Song et al., “A New Class of Biodegradable Thermosensitive Polmers. I. Synthesis and Characterization of PO;Y(Organophosphazenes) with Methoxy-Poly(Ethylene Glycol) and Amino Acid Esters as Side Groups,” Macromolecules, vol. 32, No. 7, pp. 2188-2193, 1999.

Affiliated with

Also associated with

Rating

Tumor selective and biodegradable... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor selective and biodegradable..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor selective and biodegradable... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3437824